Experimental Models of Septic Shock Therapy Affords Protection in TLR4/MD2 Monoclonal Antibody (original) (raw)

Septic shock, a severe consequence of bacterial infection, leads to high mortality rates in ICUs due to the overstimulation of the innate immune system. This study investigates the role of the TLR4/MD-2 monoclonal antibody 5E3 in providing protection against septic shock induced by LPS. Experimental models reveal that 5E3 administration results in significant inhibition of pro-inflammatory cytokines and improved survival rates in mice subjected to lethal LPS challenges. These findings suggest that targeting TLR4 and MD-2 pathways may offer promising therapeutic strategies for managing septic shock.